Funding opportunities for investigators

Multinational Clinical Trial Funding Opportunities

ECRIN can provide support to investigators for the preparation of calls for multinational clinical trial funding. If projects are funded and meet ECRIN eligibility criteria, we can subsequently offer various trial management services.

For more information on how ECRIN can support you in the preparation of these calls, see Trial Preparation and contact your local European Correspondent.

There is a dedicated page for the list of calls for funding for COVID19. It is curated by ECRIN and updated on a weekly basis. Find the relevant information here.

The calls listed below may be relevant for your applications for clinical trials / clinical research in various fields.

Note: additional information on calls on diverse topics other than clinical trials (e.g. training) may be found in the News section (select "Calls" to filter). 

Date added
23-10-2020
Deadline
14-01-2021
Description

KCE and ZonMw jointly launch a second call for the research community to submit clinical trial proposals. The available budget is 9 million euro.

In clinical practice, many treatments have not been thoroughly evaluated, making it unclear whether a patient benefits from a particular treatment, or which treatment is actually preferable. Evaluation of clinical practice is relevant to health care stakeholders in Belgium and the Netherlands and by working together, clinical evaluation trials can be carried out more quickly and efficiently. 

The aim of the BeNeFIT (Belgium-Netherlands Funding of International Trials) program is to provide funding for non-commercial practice-oriented research that is immediately relevant to patients, caregivers and policymakers in Belgium and the Netherlands and is conducted in collaboration by research institutions from both countries.

The deadline for submission of a research outline is 14 January 2021, 14.00h. 

Past Calls

Date added
30-01-2020
Deadline
12-02-2020
Description

The European Commission has issued a call to advance knowledge for the clinical and public health response to the coronavirus epidemic. The information below can be found here as well. 

Specific Challenge:
On 31 December 2019, the local authorities of Wuhan, Hubei province, China, reported a cluster of pneumonia cases of unknown origin. On 9 January 2020, the China Centre for Disease Control reported a novel Coronavirus (2019-nCoV) to be the causative agent.

As of 30 January 2020, 7824 laboratory-confirmed cases of 2019-nCoV have been reported including 170 deaths[1]. The disease has already spread to 19 countries outside China, with new cases continuing to emerge daily.

Recalling the SARS-CoV epidemic in 2003 with over 8000 cases reported (10% case fatality), it is crucial to rapidly gain a better understanding of the newly identified virus, especially in relation to potential clinical and public health measures that can be put to immediate use to improve patients’ health and/or contain the spread of 2019-nCoV.

Scope:
Proposals submitted under this expression of interest are expected to advance the knowledge on 2019-nCoV and its impact on infected persons, with the aim of contributing to an efficient patient management and/or public health preparedness and response. Proposals must be timely, with rapid activation, to enable early and valuable outcomes to be established. For increased impact, proposals may wish to build on promising avenues from previous or ongoing research.

Considering that this is a newly identified virus, the scope of this expression of interest remains broad and may include topics such as:

Development of therapeutics, including monoclonal antibodies. As relevant, evidence of regulatory and ethics approvals for the investigational products included in the study(ies) must be presented.
Development of point of care diagnostics, ensuring rapid evaluation of candidates based on existing technologies, to allow for fast case detection and surveillance.
Clinical and epidemiological studies, to provide data on epidemiological characteristics such as viral genotype and pathogenicity; clinical information on host susceptibility and host immune responses; risk factors for severe disease; routes of transmission and their relative importance; identification of the animal reservoir; etc.
Social sciences research, to provide urgently needed answers to social dynamics of the outbreak and the related public health response.
Proposals covering investigation of therapeutic and/or vaccines should consider engaging with the European Medical Agency (EMA) to ensure adequacy of the proposals from a regulatory point of view, i.e. via the innovation task force[2], scientific advice or consultation in the context of the health threats interactions[3] [4].

Where relevant, proposals should consider the close collaboration with leading European supercomputing centres to use high-end computing, data and simulation resources in order to accelerate the processes of diagnosis and vaccine research and development. In this respect, the Supercomputing facilities in Barcelona (BSC) and Bologna (Cineca) are open to collaborate with any interested proposer or successful proposal. Other leading European supercomputer centres, such as the organisations hosting the PRACE Tier-0 supercomputers, may also be interested in such collaborations.

Applicants should be aware that proposals funded under this expression of interest will be required to make available their research data, in accordance with the relevant option of Article 29.3 of the H2020 model grant agreement. The use of harmonised protocols in collaboration with other actors is recommended for this purpose.

The Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 3 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts. Please note that expenditures can be covered from the date of submission of the proposal, but at the applicant’s own risk. Proposals can be concise and should focus on the essential information to facilitate an appropriate evaluation.

Expected Impact:
To contribute to the diagnosis and clinical management of patients infected by 2019-nCoV.
To contribute to the public health preparedness and response in the context of the ongoing epidemic of 2019-nCoV.
Cross-cutting Priorities:
Socio-economic science and humanities
Gender
Open Innovation

[1]https://www.ecdc.europa.eu/en/novel-coronavirus-china

[2]https://www.ema.europa.eu/en/human-regulatory/research-development/innovation-medicines#ema's-innovation-task-force-(itf)-section

[3]https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-advice-protocol-assistance/requesting-scientific-advice-protocol-assistance-ema

[4]https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats

Date added
13-12-2019
Deadline
01-04-2020
Description

The Preliminary Announcement of the European Joint Programme on Rare Diseases (EJP RD) Joint Transnational Call (JTC) 2020 is online. The topic is: PRE-CLINICAL RESEARCH TO DEVELOP EFFECTIVE THERAPIES FOR RARE DISEASES. There will be a two-stage submission procedure for joint applications: pre-proposals and full proposals. The call is scheduled to open on December 13, 2019.

 

Date added
26-06-2019
Deadline
26-09-2019
Deadline 2
26-03-2020
Description

Call ID: H2020-JTI-IMI2-2019-18-two-stage
Action Type: RIA – Research and Innovation Actions
Topics

For full details of the topics, including the budget breakdown and the General Conditions for the Call for proposals, click on the links above (which take you directly to the relevant page of the Participant Portal) or read the IMI2 - Call 18 Text.

Indicative budget

  • From EFPIA companies and IMI2 Associated Partners: EUR 85 871 760
  • From the IMI2 JU: EUR 74 866 000

Key dates and deadlines

  • Draft topic texts published: 10 April 2019
  • Publication date: 26 June 2019
  • Stage 1 submission start date: 26 June 2019
  • Stage 1 submission deadline: 26 September 2019 (17:00:00 Brussels time)
  • Stage 2 submission deadline: 26 March 2020 (17:00:00 Brussels time)

How to apply

All documents relating to the Call can be found via the Funding and Tenders Portal and the IMI2 Call documents page, in particular the IMI Manual for evaluation, submission and grant award - version 1.7.

Detailed guidance on how to submit a proposal, including a detailed user manual and frequently asked questions, can be found under the Submit a Proposal section of the Participant Portal Horizon 2020 Online Manual.